News | Nanologica

EVENT AT NANOLOGICA’S PREMISES – NO DAMAGE TO PERSONNEL OR INSTRUMENTS

29 March, 2026

Over the weekend, a minor explosion occurred in an oven at a company that shares an office and laboratory corridor with Nanologica. The sprinkler system was activated automatically, and water was spread throughout the premises. No one has been injured and Nanologica's equipment is unharmed. The initial assessment shows that none of Nanologica's instruments or other equipment has been damaged, as water has only spread to Nanologica's premises along the floor. The incident is under

HÄNDELSE I NANOLOGICAS LOKALER – INGEN SKADA PÅ PERSONAL ELLER INSTRUMENT

29 March, 2026

Under helgen inträffade en mindre explosion i en ugn hos ett bolag som delar kontors- och laboratoriekorridor med Nanologica. Sprinklersystemet aktiverades automatiskt och vatten spreds i lokalerna. Ingen person har kommit till skada och Nanologicas utrustning är oskadd. Den initiala bedömningen visar att inga av Nanologicas instrument eller annan utrustning har skadats, eftersom vatten endast spridits till Nanologicas lokaler längs golvet. Händelsen är under kontroll och utredning pågår för att fastställa den exakta orsaken. Nanologicas

Nanologica Announces Outcome of Rights Issue

26 March, 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRAVENES APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH

Nanologica offentliggör utfall i företrädesemission

26 March, 2026

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN DISTRIBUTION KRÄVER PROSPEKT, REGISTRERING ELLER ANDRA ÅTGÄRDER UTÖVER DE SOM FÖLJER AV SVENSK RÄTT, ÄR FÖRBJUDEN, ELLER ANNARS STRIDER MOT TILLÄMPLIGA REGLER I SÅDAN JURISDIKTION ELLER INTE KAN SKE UTAN TILLÄMPNING AV UNDANTAG FRÅN SÅDAN ÅTGÄRD. SE AVSNITTET "VIKTIG INFORMATION" I SLUTET

The Nomination Committee Proposes Election of Mark Quick and Erik Haeffler as New Board Members of Nanologica AB (publ)

10 March, 2026

The nomination committee of Nanologica proposes to the Annual General Meeting on May 21 that Mark Quick and Erik Haeffler be elected as new members of the board of directors of Nanologica AB. Furthermore, Thomas Eldered is proposed as new chairman of the board. Mark Quick works as a Partner at Flerie AB having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. Prior to that he held positions

Valberedningen föreslår nyval av Mark Quick och Erik Haeffler som styrelseledamöter i Nanologica AB (publ)

10 March, 2026

Valberedningen i Nanologica föreslår inför årsstämman den 21 maj att Mark Quick och Erik Haeffler väljs som nya styrelseledamöter i Nanologica AB. Vidare föreslås Thomas Eldered som ny ordförande. Mark Quick arbetar som partner på Flerie AB och kommer från en tidigare roll på Recipharm där han var chef för företagsutveckling och ledde M&A-aktiviteterna. Innan dess har Mark Quick innehaft positioner inom ICI, Medeva, Celltech och UCB i olika roller inom affärsutveckling och leveranskedja. Han

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.